茶山 弘美HIROMI CHAYAMA

Last Updated :2018/11/01

所属・職名
大学院医歯薬保健学研究科(医) 大学院医歯薬保健学研究院 准教授
メールアドレス
habehiroshima-u.ac.jp

基本情報

学位

  • 博士(医学) (広島大学)

研究分野

  • 工学 / プロセス・化学工学 / 生物機能・バイオプロセス
  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

教育活動

授業担当

  1. 2018年, 修士課程・博士課程前期, セメスター(前期), 基礎生命科学コースワーク
  2. 2018年, 修士課程・博士課程前期, セメスター(前期), 基礎生命科学コースワーク
  3. 2018年, 修士課程・博士課程前期, セメスター(前期), 基礎生命科学コースワーク
  4. 2018年, 修士課程・博士課程前期, セメスター(前期), 基礎生命科学コースワーク
  5. 2018年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  6. 2018年, 博士課程・博士課程後期, セメスター(後期), スタートアップ生命科学コースワーク
  7. 2018年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  8. 2018年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  9. 2018年, 博士課程・博士課程後期, セメスター(前期), スタートアップ生命科学コースワーク
  10. 2018年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  11. 2018年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  12. 2018年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク
  13. 2018年, 博士課程・博士課程後期, セメスター(後期), アドバンスド生命科学コースワーク

研究活動

学術論文(★は代表的な論文)

  1. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17巻, 8号, pp.1551-pp.1561, 2012
  2. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 205巻, 2号, pp.204-pp.210, JAN 15 2012
  3. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19巻, 2号, pp.E126-pp.E133, FEB 2012
  4. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56巻, 2号, pp.555-pp.566, AUG 2012
  5. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47巻, 7号, pp.834-pp.844, JUL 2012
  6. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7巻, 10号, OCT 16 2012
  7. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C, JOURNAL OF GENERAL VIROLOGY, 94巻, pp.81-pp.89, JAN 2013
  8. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85巻, 5号, pp.789-pp.798, MAY 2013
  9. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region, JOURNAL OF HEPATOLOGY, 58巻, 5号, pp.875-pp.882, MAY 2013
  10. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62巻, 7号, pp.1055-pp.1061, JUL 2013
  11. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108巻, 9号, pp.1464-pp.1472, SEP 2013
  12. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48巻, 10号, pp.1188-pp.1204, OCT 2013
  13. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441巻, 1号, pp.230-pp.235, NOV 8 2013
  14. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN- expression and inducing IL-22, INTERNATIONAL IMMUNOLOGY, 26巻, 3号, pp.129-pp.137, MAR 2014
  15. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir., J Hepatol., 58巻, pp.646-pp.654, 20130501
  16. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., J Infect Dis., 204巻, pp.224-pp.228, 20110401
  17. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PLoS One., 6巻, pp.e23856, 20110801
  18. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., J Hepatol., 54巻, pp.872-pp.878, 20110501
  19. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations., J Gen Virol., 92巻, pp.1071-pp.1081, 20110801
  20. ★, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers., Nat Genet., 43巻, pp.797-pp.800, 20111001
  21. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population., Hum Mol Genet., 20巻, pp.3884-pp.3892, 20110301
  22. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b., J Hepatol., 54巻, pp.408-pp.414, 20110901
  23. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology., 54巻, pp.781-pp.788, 20110901
  24. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology., 54巻, pp.764-pp.771, 20110201
  25. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut., 60巻, pp.261-pp.267, 20110101
  26. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol., 83巻, pp.981-pp.988, 20110401
  27. A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients., J Hepatol., 54巻, pp.629-pp.639, 20110101
  28. Animal model for study of human hepatitis viruses., J Gastroenterol Hepatol., 26巻, pp.13-pp.18, 20110701
  29. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C., J Infect Dis., 204巻, pp.84-pp.93, 20110601
  30. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol., 83巻, pp.1048-pp.1057, 20110701
  31. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., J Hepatol., 55巻, pp.41596, 20110901
  32. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state., J Med Virol., 83巻, pp.1597-pp.1607, 20110601
  33. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy., J Hepatol., 54巻, pp.1094-pp.1101, 20110501
  34. G to A hypermutation of TT virus., Virus Res., 149巻, pp.211-pp.216, 20100701
  35. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., J Gen Virol., 91巻, pp.1854-pp.1864, 20101001
  36. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients., Gastroenterology., 139巻, pp.1190-pp.1197, 20100801
  37. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrob Agents Chemother., 54巻, pp.3205-pp.3211, 20100401
  38. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antivir Ther., 15巻, pp.1087-pp.1097, 20100401
  39. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B., Antivir Ther., 15巻, pp.177-pp.184, 20100901
  40. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients., J Hepatol., 53巻, pp.439-pp.443, 20100501
  41. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C., Gastroenterology., 136巻, pp.1796-pp.1805, 20090601
  42. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., J Infect Dis., 199巻, pp.1599-pp.1607, 20091201
  43. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., J Hepatol., 51巻, pp.1046-pp.1054, 20091201
  44. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection., Hepatol Res., 39巻, pp.1159-pp.1168, 20090901
  45. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., J Gen Virol., 89巻, pp.2108-pp.2113, 20080101
  46. Successful treatment of an entecavir-resistant hepatitis B virus variant., J Med Virol., 79巻, pp.1811-pp.1817, 20070201
  47. Dual effect of APOBEC3G on Hepatitis B virus., J Gen Virol., 88巻, pp.432-pp.440, 20070501
  48. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS Lett., 581巻, pp.1983-pp.1987, 20070501
  49. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology., 45巻, pp.1179-pp.1186, 20071101
  50. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrob Agents Chemother., 50巻, pp.3867-pp.3874, 20061201
  51. Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients treated with daclatasvir, peg-interferon and ribavirin, Antimicrob Agents Chemother, 20140101
  52. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLoS One, 8巻, 12号, pp.e84226, 20131201
  53. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, J Gastroenterol, 20131201
  54. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B, ANTIVIRAL THERAPY, 15巻, 2号, pp.177-pp.184, 2010
  55. G to A hypermutation of TT virus, VIRUS RESEARCH, 149巻, 2号, pp.211-pp.216, MAY 2010
  56. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91巻, pp.1854-pp.1864, JUL 2010
  57. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54巻, 5号, pp.872-pp.878, MAY 2011
  58. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54巻, 8号, pp.3205-pp.3211, AUG 2010
  59. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53巻, 3号, pp.439-pp.443, SEP 2010
  60. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15巻, 8号, pp.1087-pp.1097, 2010
  61. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54巻, 3号, pp.408-pp.414, MAR 2011
  62. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients, JOURNAL OF HEPATOLOGY, 54巻, 4号, pp.629-pp.639, APR 2011
  63. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54巻, 3号, pp.781-pp.788, SEP 2011
  64. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp.981-pp.988, JUN 2011
  65. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp.1048-pp.1057, JUN 2011
  66. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations, JOURNAL OF GENERAL VIROLOGY, 92巻, pp.1071-pp.1081, MAY 2011
  67. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54巻, 6号, pp.1094-pp.1101, JUN 2011
  68. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55巻, 1号, pp.11-pp.18, JUL 2011
  69. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 204巻, 1号, pp.84-pp.93, JUL 1 2011
  70. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83巻, 9号, pp.1597-pp.1607, SEP 2011
  71. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, NATURE GENETICS, 43巻, 8号, pp.797-pp.U108, AUG 2011
  72. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6巻, 8号, AUG 23 2011
  73. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54巻, 3号, pp.764-pp.771, SEP 2011
  74. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population, HUMAN MOLECULAR GENETICS, 20巻, 19号, pp.3884-pp.3892, OCT 1 2011
  75. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice, NEUROCHEMISTRY INTERNATIONAL, 60巻, 8号, pp.817-pp.826, JUN 2012
  76. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58巻, 4号, pp.2105-pp.2112, APR 2014
  77. Aryl hydrocarbon receptor protects against bacterial infection by promoting macrophage survival and reactive oxygen species production, INTERNATIONAL IMMUNOLOGY, 26巻, 4号, pp.209-pp.220, APR 2014
  78. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21巻, 9号, pp.E89-pp.E97, SEP 2014
  79. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, JOURNAL OF GENERAL VIROLOGY, 95巻, pp.1297-pp.1306, JUN 2014
  80. New Insight Into the Enhanced Effect of Pegylated Interferon-alpha, HEPATOLOGY, 60巻, 4号, pp.1435-pp.1437, OCT 2014
  81. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp.1548-pp.1556, DEC 2014
  82. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70巻, 3号, pp.273-pp.287, MAR 2015
  83. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 3号, pp.619-pp.627, MAR 2015
  84. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp.158-pp.165, FEB 2015
  85. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp.166-pp.174, FEB 2015
  86. Novel Robust in Vitro Hepatitis B Virus Infection Model Using Fresh Human Hepatocytes Isolated from Humanized Mice, AMERICAN JOURNAL OF PATHOLOGY, 185巻, 5号, pp.1275-pp.1285, MAY 2015
  87. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10巻, 6号, JUN 17 2015
  88. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy, ANTIVIRAL THERAPY, 20巻, 4号, pp.369-pp.375, 2015
  89. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63巻, 3号, pp.554-pp.563, SEP 2015
  90. Effects of sesamin and capsaicin on the mRNA expressions of delta6 and delta5 desaturases in rat primary cultured hepatocytes., Journal of nutritional science and vitaminology, 49巻, 6号, 2003
  91. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrobial agents and chemotherapy, 50巻, 11号, 2006
  92. Dual effect of APOBEC3G on Hepatitis B virus., The Journal of general virology, 88巻, Pt 2号, 2007
  93. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology (Baltimore, Md.), 45巻, 5号, 2007
  94. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS letters, 581巻, 10号, 2007
  95. Successful treatment of an entecavir-resistant hepatitis B virus variant., Journal of medical virology, 79巻, 12号, 2007
  96. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., The Journal of general virology, 89巻, Pt 9号, 2008
  97. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., The Journal of infectious diseases, 199巻, 11号, 2009
  98. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., Journal of hepatology, 51巻, 6号, 2009
  99. G to A hypermutation of TT virus., Virus research, 149巻, 2号, 2010
  100. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., The Journal of general virology, 91巻, Pt 7号, 2010
  101. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrobial agents and chemotherapy, 54巻, 8号, 2010
  102. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., Journal of hepatology, 54巻, 5号, 2011
  103. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., Journal of hepatology, 55巻, 1号, 2011
  104. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antiviral therapy, 15巻, 8号, 2010
  105. Animal model for study of human hepatitis viruses., Journal of gastroenterology and hepatology, 26巻, 1号, 2011
  106. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., Journal of medical virology, 83巻, 6号, 2011
  107. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology (Baltimore, Md.), 54巻, 3号, 2011
  108. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology (Baltimore, Md.), 54巻, 3号, 2011
  109. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., The Journal of infectious diseases, 204巻, 2号, 2011
  110. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PloS one, 6巻, 8号, 2011
  111. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse., Hepatology (Baltimore, Md.), 56巻, 2号, 2012
  112. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients., Journal of gastroenterology, 47巻, 7号, 2012
  113. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice., Neurochemistry international, 60巻, 8号, 2012
  114. Identification of novel HCV deletion mutants in chronic hepatitis C patients., Antiviral therapy, 17巻, 8号, 2012
  115. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle., PloS one, 7巻, 10号, 2012
  116. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice., Gut, 62巻, 7号, 2013
  117. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients., Journal of gastroenterology, 48巻, 10号, 2013
  118. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B., Journal of medical virology, 85巻, 5号, 2013
  119. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing., The American journal of gastroenterology, 108巻, 9号, 2013
  120. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections., Biochemical and biophysical research communications, 441巻, 1号, 2013
  121. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., Journal of gastroenterology, 49巻, 12号, 2014
  122. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study., PloS one, 8巻, 12号, 2013
  123. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin., Antimicrobial agents and chemotherapy, 58巻, 4号, 2014
  124. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population., The Journal of general virology, 95巻, Pt 6号, 2014
  125. New insight into the enhanced effect of pegylated interferon-α., Hepatology (Baltimore, Md.), 60巻, 4号, 2014
  126. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway., Journal of gastroenterology and hepatology, 30巻, 3号, 2015
  127. Differences in serum microRNA profiles in hepatitis B and C virus infection., The Journal of infection, 70巻, 3号, 2015
  128. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice., The American journal of pathology, 185巻, 5号, 2015
  129. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A., Journal of hepatology, 63巻, 3号, 2015
  130. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy., Journal of medical virology, 87巻, 11号, 2015
  131. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay., PloS one, 10巻, 6号, 2015
  132. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice., Journal of virology, 89巻, 19号, 2015
  133. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones., The Journal of infection, 72巻, 1号, 2016
  134. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice., Antiviral therapy, 21巻, 4号, 2016
  135. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice., Virus research, 213巻, 2016
  136. Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders., The international journal of neuropsychopharmacology, 19巻, 9号, 2016
  137. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection., Journal of gastroenterology, 51巻, 11号, 2016
  138. Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates., Hepatology (Baltimore, Md.), 64巻, 4号, 2016
  139. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing., The Journal of infectious diseases, 214巻, 11号, 2016
  140. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology., The Journal of general virology, 98巻, 5号, 2017
  141. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy., Cellular and molecular gastroenterology and hepatology, 1巻, 5号, 2015
  142. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus., PloS one, 12巻, 3号, 2017
  143. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus., Antimicrobial agents and chemotherapy, 61巻, 6号, 2017
  144. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53巻, 1号, 2018
  145. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53巻, 1号, 2018
  146. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice., Antimicrobial agents and chemotherapy, 61巻, 9号, 2017
  147. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease., Journal of gastroenterology, 53巻, 2号, 2018
  148. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients., Antiviral therapy, 23巻, 3号, 2018
  149. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice., Biochemical and biophysical research communications, 500巻, 2号, 2018
  150. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study., Antiviral therapy, 2018
  151. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure., The Journal of general virology, 99巻, 8号, 2018
  152. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients., Journal of viral hepatitis, 2018

外部資金

競争的資金等の採択状況

  1. 民間からの助成金, IL28B 遺伝子多型の生物学的効果の機序解明に関する研究, 2011年
  2. 科学研究費助成事業(基盤研究(C)), ヒト肝細胞キメラマウスとバキュロウイルスを用いた遺伝病モデルの創生, 2014年, 2016年
  3. 科学研究費助成事業(若手研究(B)), ヒト肝細胞キメラマウスと次世代シーケンサーを用いた肝炎ウイルスゲノムの解析, 2012年, 2013年
  4. 科学研究費助成事業(若手研究(B)), IL-28BのSNPとHCV遺伝子に関する研究, 2010年, 2011年
  5. 平成30年度地球規模保健課題解決推進のための研究事業, 2018年, 2019年